Management of pituitary tumors in pregnancy

Nat Rev Endocrinol. 2011 May;7(5):301-10. doi: 10.1038/nrendo.2011.38. Epub 2011 Mar 15.

Abstract

Pituitary tumors, usually adenomas, account for about 10-15% of all intracranial tumors. Their treatment, which includes surgery, medicine or radiotherapy, either isolated or in combination, aims to halt tumor growth or achieve tumor shrinkage, as well as control hormone hypersecretion or ensure hormone replacement. Such approaches have made pregnancy possible for women with pituitary adenomas. Medical therapy with dopamine agonists is the treatment of choice for most patients with prolactinomas, with surgery reserved for individuals resistant to drugs. On the other hand, surgery before conception is indicated as a first-line approach in patients with acromegaly, Cushing disease or clinically nonfunctioning pituitary macroadenomas. In these patient populations, medical therapy with somatostatin analogues (acromegaly) or drugs that target the adrenal glands, such as metyrapone and ketoconazole (Cushing disease), should be reserved for those in whom surgery is unsuccessful or contraindicated.

Publication types

  • Review

MeSH terms

  • Dopamine Agonists / therapeutic use
  • Female
  • Humans
  • Ketoconazole / therapeutic use
  • Metyrapone / therapeutic use
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / radiotherapy
  • Pituitary Neoplasms / surgery*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy
  • Pregnancy Complications, Neoplastic / radiotherapy
  • Pregnancy Complications, Neoplastic / surgery

Substances

  • Dopamine Agonists
  • Ketoconazole
  • Metyrapone